Compare
CVS Health vs NeoGenomics Laboratories (CVS vs NEO)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year CVS Health (CVS) returned +6.8% and NeoGenomics Laboratories (NEO) +61.5%; so far this year the figures are +5.7% and +43.2%.
CVS Health is the larger company by market value, about 49.2 times the size of NeoGenomics Laboratories.
Revenue grew +6.7% at CVS and +11.1% at NEO over the last year.
CVS yields 3.17%. NEO pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| CVS | NEO | |
|---|---|---|
| Price | $83.85 | $16.84 |
| 1-day | +3.10% | +2.12% |
| YTD | +5.66% | +43.20% |
| 1 year | +6.75% | +61.46% |
| 3 years | +22.00% | +22.29% |
| Market cap | $107.3B | $2.2B |
| P/E | 9.7 | — |
| P/S | 0.26 | 2.77 |
| P/B | 1.33 | 2.72 |
| Revenue growth | +6.70% | +11.10% |
| EPS growth | +2107.70% | — |
| Gross margin % | 44.2 | 44.8 |
| Net margin % | 2.6 | -4.1 |
| ROE % | 13.7 | -4.0 |
| Debt / equity | 0.75 | 0.47 |
| FCF yield % | 14.5 | -1.3 |
| Dividend yield % | 3.17 | — |
| Beta | -0.06 | 1.08 |
| RSI (14) | 39.9 | 47.7 |
| Technical rating |